Belzutifan

编号: 20606

Cas号: 1672668-24-4

纯度: 98% Min.

Belzutifan, also known as PT2977 and MK-6482, is HIF-2alpha inhibitor. PT2977 binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis. Belzutifan was approved in 2021 for treatment of von Hippel-Lindau disease under certain conditions

仅供研究使用。我们不向患者出售。

化学信息

名称	Belzutifan
Iupac 化学名称	3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile
同义词	MK-6482; MK 6482; MK6482; PT2977; PT-2977; PT 2977; Belzutifan
英文同义词	MK-6482; MK 6482; MK6482; PT2977; PT-2977; PT 2977; Belzutifan
分子式	C17H12F3NO4S
分子量	383.34
Smile	N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2[C@@H](F)[C@@H](F)[C@H]3O)=C1
InChiKey	LOMMPXLFBTZENJ-ZACQAIPSSA-N
InChi	InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
Cas号	1672668-24-4
相关CAS号

订购信息

包装	价格	库存	纯度	备货期
大货		询价	询价	询价

Request Bulk Quote Download MSDS 电话 : +86-177 0271 9238 Email : sales@sun-shinechem.com

外观性状	固体粉末
纯度	98% Min.
存储	短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度
可溶性	溶于DMSO
处理方式
运输条件	作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周.
海关编码

Coming soon.

Targets
Mechanism
Cell study
Animal study
Clinical study

1: Deeks ED. Belzutifan: First Approval. Drugs. 2021 Nov;81(16):1921-1927. doi: 10.1007/s40265-021-01606-x. PMID: 34613603.

2: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. PMID: 34818478; PMCID: PMC9275515.

3: Visweswaran V, Pavithran K. Belzutifan: A Narrative Drug Review. Curr Drug Res Rev. 2022;14(2):88-95. doi: 10.2174/2589977514666220401094724. PMID: 35366789.

4: Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22. Erratum in: Nat Med. 2021 Oct;27(10):1849. PMID: 33888901; PMCID: PMC9128828.

5: Belzutifan. Am J Health Syst Pharm. 2021 Dec 9;78(24):2185-2187. doi: 10.1093/ajhp/zxab366. PMID: 34718390.

6: Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors. Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054. PMID: 35727604; PMCID: PMC9669093.

7: Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, Imamovic A, Wall CB, Wassner AJ, Weil BR, Heeney MM, Vargas SO, Kaelin WG Jr, Janeway KA, Perini RF, Zojwalla NJ, Voss SD, DuBois SG. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 Nov 25;385(22):2059-2065. doi: 10.1056/NEJMoa2110051. PMID: 34818480.

8: Choi WW, Boland JL, Kalola A, Lin J. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors. Curr Oncol Rep. 2023 Feb;25(2):123-129. doi: 10.1007/s11912-022-01354-5. Epub 2023 Jan 11. PMID: 36630072.

9: Romero D. Belzutifan is active in VHL-related cancers. Nat Rev Clin Oncol. 2022 Feb;19(2):72. doi: 10.1038/s41571-021-00587-w. PMID: 34893759.

10: McCabe EM, Lee S, Rasmussen TP. Belzutifan (Welireg™) for von Hippel Lindau disease. Trends Pharmacol Sci. 2022 Oct;43(10):882-883. doi: 10.1016/j.tips.2022.05.002. Epub 2022 Jun 9. PMID: 35691787.

11: Romero D. Belzutifan has potential in RCC. Nat Rev Clin Oncol. 2021 Jun;18(6):322. doi: 10.1038/s41571-021-00517-w. PMID: 33931768.

12: Cowman SJ, Koh MY. Revisiting the HIF switch in the tumor and its immune microenvironment. Trends Cancer. 2022 Jan;8(1):28-42. doi: 10.1016/j.trecan.2021.10.004. Epub 2021 Nov 4. PMID: 34743924; PMCID: PMC8702465.

13: Pelle E, Al-Toubah T, Morse B, Strosberg J. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor. J Natl Compr Canc Netw. 2022 Dec;20(12):1285-1287. doi: 10.6004/jnccn.2022.7047. PMID: 36509068.

14: Zhou J, Gong K. Belzutifan: a novel therapy for von Hippel-Lindau disease. Nat Rev Nephrol. 2022 Apr;18(4):205-206. doi: 10.1038/s41581-022-00544-5. PMID: 35132216.

15: Bensalah K, Khene ZE, Massard C. Re: Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. Eur Urol. 2022 May;81(5):545-546. doi: 10.1016/j.eururo.2022.01.014. Epub 2022 Jan 31. PMID: 35094899.

16: Dhawan A, Peereboom DM, Stevens GH. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma. CNS Oncol. 2022 Jul 12;11(3):CNS91. doi: 10.2217/cns-2022-0008. Epub ahead of print. PMID: 35819008; PMCID: PMC9280404.

17: Wang K, Crona J, Beuschlein F, Grossman AB, Pacak K, Nölting S. Targeted Therapies in Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972. doi: 10.1210/clinem/dgac471. PMID: 35973976; PMCID: PMC9923802.

18: FDA OK's HIF2α Inhibitor Belzutifan. Cancer Discov. 2021 Oct;11(10):2360-2361. doi: 10.1158/2159-8290.CD-NB2021-0377. Epub 2021 Sep 3. PMID: 34479868.

19: Arevalo A, Patel N, Muraki P, Ohtake S, Bratslavsky G, Clark C, Mann J, Iliopoulos O, Jonasch E, Srinivasan R, Shuch B. Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL. J Kidney Cancer VHL. 2022 Sep 28;9(3):41-46. doi: 10.15586/jkcvhl.v9i3.245. PMID: 36310638; PMCID: PMC9551368.

20: Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8. PMID: 36752726.

化学结构

Belzutifan

化学信息

订购信息

化学结构

快速订购

产品目录